Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis
DOI:
https://doi.org/10.3329/jemc.v6i3.29685Keywords:
Sulfasalazine, Ulcerative colitis, Pancytopenia, MyelosuppressionAbstract
Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.
J Enam Med Col 2016; 6(3): 164-165
Downloads
53
121
Downloads
Published
How to Cite
Issue
Section
License
- Copyright on any research article is transferred in full to Journal of Enam Medical College upon publication in the journal. The copyright transfer includes the right to reproduce and distribute the article in any form of reproduction (printing, electronic media or any other form).
- Articles in the Journal of Enam Medical College are Open Access articles published under the Creative Commons CC BY License (https://creativecommons.org/licenses/by/4.0/)
- This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.